12 were enrolled into each of the 1 g , 2 g , or 5 g plus 25 g idarucizumab groups ( nine to idarucizumab and three to placebo in each group ) , and 11 were enrolled into the 4 g idarucizumab group ( eight to idarucizumab and three to placebo ) .